HLB Therapeutics Completes Patient Procedures in Global Phase 3 'SEER-2' Trial of RGN-259... Targets November Topline Data Release
HLB Therapeutics has completed all patient procedures in the global Phase 3 clinical trial of 'RGN-259', a candidate treatment for neurotrophic keratitis, and has entered the data analysis stage. The company aims to obtain top-line results within November. ■ Last Patient Last Visit (LPLV) Completed

HLB Therapeutics has completed all patient procedures in the global Phase 3 clinical trial of 'RGN-259', a candidate treatment for neurotrophic keratitis, and has entered the data analysis stage. The company aims to obtain top-line results within November.
■ Last Patient Last Visit (LPLV) Completed... Data Analysis Underway in Earnest
HLB Therapeutics announced that it has completed the Last Patient Last Visit (LPLV) in the global Phase 3 clinical trial 'SEER-2' of RGN-259, being conducted by its U.S. subsidiary ReGenTree. LPLV is a procedure in which final adverse event and safety evaluations are completed for the last dosed patient, and with its completion, the clinical process involving patients has concluded.
Data organization, verification, and statistical analysis will now proceed in full swing. ReGenTree has been sequentially collecting and cleaning data from clinical sites where patient enrollment was completed, and plans to accelerate the remaining data organization and analysis procedures following the LPLV completion.
■ Phase 3 Trial Conducted at 50 Medical Institutions Across the U.S. and Europe
SEER-2 is a global Phase 3 clinical trial designed to evaluate the corneal wound healing effect and safety of RGN-259 in patients with neurotrophic keratitis (NK). The trial was conducted at a total of 50 medical institutions, including 41 hospitals in the United States and 9 hospitals in three European countries: Italy, Spain, and Poland.
ReGenTree aims to confirm top-line results within November, based on the data organization and analysis schedule proposed by its contract research organization (CRO).
■ Eye Drop Formulation with Thymosin Beta 4 as Active Ingredient... Targeting a Disease with No Approved Treatments
RGN-259 is a new drug candidate in the form of eye drops with thymosin beta 4, a regeneration-promoting protein, as its active ingredient. Based on a mechanism that promotes corneal wound healing and nerve regeneration, it is being developed as a treatment for neurotrophic keratitis.
Neurotrophic keratitis is a rare degenerative eye disease in which corneal sensation and natural healing ability are impaired due to damage to the corneal nerves. As the disease progresses, persistent corneal epithelial defects or ulcers may occur, and in severe cases, it can lead to corneal perforation or vision loss. As currently available approved treatments are limited, the field is regarded as one with high medical demand for new therapeutic options.
■ November Topline Data a Key Factor Going Forward
Market attention is expected to focus on the top-line data scheduled for release in November. With patient-related clinical procedures now completed, the results RGN-259 demonstrates in key efficacy endpoints are expected to be a critical variable in determining future development timelines and business value.
[※ This article was written based on materials released by the company. Clinical trial results and new drug development timelines may change depending on future data analysis and regulatory review processes. This article does not recommend the purchase or sale of any specific stock or guarantee investment returns. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Jusung Engineering Surges Over 9% Despite Intraday VI Trigger... Draws Attention Amid KOSDAQ Strength](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F09%2F610076%2Ff79c71c7d0fb71df%2Fvariants%2Fhero.webp&w=1920&q=75)
